Business Activities
Research and Development
Research
Mochida's Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.
Development
Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.
Pipeline
| Code | Name | Indications | Formulation | Stage | Remarks |
|---|---|---|---|---|---|
| AJH801 | cilnidipine/ valsartan combination |
Hypertension | Oral | Filed | Co-development with Ajinomoto Pharmaceuticals |
| MD-0901 | mesalazine | Ulcerative colitis | Oral | Phase III | Licensed-in from Shire Pharmaceuticals Group （UK） |
| MLD-55 | escitalopram | Social anxiety disorder | Oral | Phase III | Licensed-in from Lundbeck (Denmark) |
| MD-0701 | treprostinil | Pulmonary arterial hypertension | Injection | Phase II/III | Originator: United Therapeutics (USA) |
| MND-21 | ethyl icosapentate |
Non-alcoholic steatohepatitis | Oral | Phase II completed | |
| MJR-35 | dienogest | Uterine adenomyosis | Oral | Late Phase II | Licensed-in from Jenapharm (Bayer Pharma AG) |